Lawrenceville, NJ , Jan. 26, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the closing of its previously announced registered direct offering of 25,925,925 shares of common stock at a purchase price of $1.35 per share, priced

LAWRENCEVILLE, NJ , Jan. 22, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into definitive agreements with institutional investors for the purchase and sale of 25,925,925 shares of its common stock at a purchase price of

         Initiates Phase II OVATION 2 Study of GEN-1 in Advanced Ovarian Cancer Continues Following Patients for Overall Survival in Phase III OPTIMA Study Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J , Nov. 16, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:

LAWRENCEVILLE, N.J. , Nov. 09, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the third quarter ended September 30, 2020 and provide an update on its development programs for GEN-1, an IL-12

CEO Provides Updates on Phase III OPTIMA Study Data Analysis and ThermoDox ® Investigator-Sponsored Studies LAWRENCEVILLE, N.J. , Oct. 12, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that Michael H.

Agreement Includes 1 Million Shares Purchased at 28% Market Premium LAWRENCEVILLE, N.J , Sept. 08, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today provided an update on the OVATION 2 Study with GEN-1 in advanced ovarian cancer patients.

Completes New $5 Million Loan Agreement with Market Competitive Terms and Debt Reduction Consistent with Celsion’s Capitalization New Agreement Ensures A Strong Balance Sheet and Additional Operating Runway LAWRENCEVILLE, N.J. , Sept. 02, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN)

Initiates Promising Phase II Study of GEN-1 in Advanced Ovarian Cancer Will Continue Following Patients in Phase III OPTIMA Study for Overall Survival; Data Maturity at Issue Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J , Aug.

LAWRENCEVILLE, N.J , Aug. 07, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the second quarter ended June 30, 2020 and provide an update on its development programs for GEN-1, an IL-12 DNA

Ongoing Analysis of Unblinded Study Data Suggests Data Maturity May be at Issue Cohort of 26 Consecutive Patient Deaths Differs Substantially from Predicted Behavior and from the Balance of the Trial LAWRENCEVILLE, N.J. , Aug. 04, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , an